MCID: AMY004
MIFTS: 71

Amyloidosis

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Amyloidosis

MalaCards integrated aliases for Amyloidosis:

Name: Amyloidosis 12 59 55 6 43 44 15 17 72 33
Amyloid Disease 12

Characteristics:

Orphanet epidemiological data:

59
amyloidosis
Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:9120
ICD9CM 35 277.3 277.30
MeSH 44 D000686
NCIt 50 C2868
SNOMED-CT 68 17602002
ICD10 33 E85 E85.9
MESH via Orphanet 45 D000686
ICD10 via Orphanet 34 E85.0 E85.1 E85.2 more
UMLS via Orphanet 73 C0002726
Orphanet 59 ORPHA69
UMLS 72 C0002726

Summaries for Amyloidosis

MedlinePlus : 43 Amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. The deposits can collect in organs such as the kidney and heart. This can cause the organs to become stiff and unable to work the way they should. There are three main types of amyloidosis: Primary - with no known cause Secondary - caused by another disease, including some types of cancer Familial - passed down through genes Symptoms can vary, depending upon which organs are affected. Treatment depends on the type of amyloidosis you have. The goal is to help with symptoms and limit the production of proteins. If another disease is the cause, it needs to be treated.

MalaCards based summary : Amyloidosis, also known as amyloid disease, is related to amyloidosis, hereditary, transthyretin-related and amyloidosis, finnish type. An important gene associated with Amyloidosis is TTR (Transthyretin), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Colchicine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and liver, and related phenotypes are facial palsy and protruding ear

Disease Ontology : 12 An acquired metabolic disease that has material basis in extracellular tissue deposition of mis-folded proteins called fibrils composed of low molecular weight subunits of a variety of proteins. These deposits may result in a wide range of clinical manifestations depending upon their type, location, and the amount of deposition.

Wikipedia : 75 Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in... more...

Related Diseases for Amyloidosis

Diseases in the Amyloidosis family:

Al Amyloidosis Amyloidosis Aa
Hereditary Amyloidosis Primary Localized Amyloidosis
Ah Amyloidosis

Diseases related to Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1390)
# Related Disease Score Top Affiliating Genes
1 amyloidosis, hereditary, transthyretin-related 35.4 TTR GSN APOA1
2 amyloidosis, finnish type 35.0 TTR GSN APOE
3 al amyloidosis 34.9 TTR LYZ CST3 B2M
4 hereditary amyloidosis 34.4 TTR LYZ GSN FGA B2M APOA1
5 lichen amyloidosis 34.2 OSMR IL31RA GPNMB
6 macular amyloidosis 34.2 OSMR IL31RA GPNMB
7 cerebral amyloid angiopathy, app-related 34.2 CST3 APP
8 muckle-wells syndrome 34.1 TNFRSF1A NLRP3 MEFV
9 amyloidosis aa 33.7 TTR SAA4 SAA2 SAA1 MEFV B2M
10 periodic fever, familial, autosomal dominant 33.2 TNFRSF1A NLRP3 MEFV LYZ
11 hereditary cerebral amyloid angiopathy 33.1 CST3 APP
12 familial cold autoinflammatory syndrome 1 33.0 TNFRSF1A NLRP3 MEFV
13 cerebral amyloid angiopathy, cst3-related 32.8 TTR SERPINA3 GSN CST3 APP APOE
14 familial mediterranean fever 32.4 TNFRSF1A SAA4 SAA2 SAA1 NLRP3 MEFV
15 polyneuropathy 32.1 TTR GSN APOA1
16 amyloidosis, familial visceral 32.1 TTR TNFRSF1A SAA4 SAA2 SAA1 MEFV
17 cryopyrin-associated periodic syndrome 31.8 SAA4 NLRP3
18 hyper-igd syndrome 31.8 TNFRSF1A SAA1
19 hemorrhage, intracerebral 30.8 CST3 APP APOE
20 wells syndrome 30.6 TNFRSF1A NLRP3 MEFV
21 blepharochalasis 30.6 TTR SAA1 OSMR GSN
22 vascular disease 30.1 FGA CST3 APOE APOA1
23 senile plaque formation 30.1 APP APOE
24 alzheimer's disease 1 30.0 APP APOE
25 cerebrovascular disease 29.9 APP APOE APOA1
26 creutzfeldt-jakob disease 29.7 SERPINA3 CST3 APOE
27 alzheimer disease 29.7 TTR TNFRSF1A SERPINA3 CST3 APP APOE
28 nervous system disease 29.4 TTR APP APOE
29 primary cutaneous amyloidosis 12.8
30 amyloidosis, primary localized cutaneous, 1 12.8
31 amyloidosis, primary localized cutaneous, 3 12.7
32 amyloidosis, primary localized cutaneous, 2 12.6
33 familial amyloidosis, finnish type 12.5
34 wild type attr amyloidosis 12.5
35 aapoaii amyloidosis 12.4
36 afib amyloidosis 12.4
37 variant abeta2m amyloidosis 12.4
38 aapoai amyloidosis 12.4
39 wild type abeta2m amyloidosis 12.4
40 myeloma, multiple 12.4
41 primary localized amyloidosis 12.4
42 ah amyloidosis 12.4
43 alect2 amyloidosis 12.4
44 aapoaiv amyloidosis 12.3
45 amyloidosis beta2m 12.3
46 hereditary transthyretin amyloidosis 12.3
47 nodular cutaneous amyloidosis 12.3
48 amyloidosis nodular localized cutaneous 12.2
49 obsolete: hepatic amyloidosis with intrahepatic cholestasis 12.2
50 corneal dystrophy, gelatinous drop-like 12.2

Comorbidity relations with Amyloidosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease

Graphical network of the top 20 diseases related to Amyloidosis:



Diseases related to Amyloidosis

Symptoms & Phenotypes for Amyloidosis

Human phenotypes related to Amyloidosis:

59 32 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 facial palsy 59 32 hallmark (90%) Very frequent (99-80%) HP:0010628
2 protruding ear 59 32 hallmark (90%) Very frequent (99-80%) HP:0000411
3 corneal dystrophy 59 32 hallmark (90%) Very frequent (99-80%) HP:0001131
4 everted lower lip vermilion 59 32 hallmark (90%) Very frequent (99-80%) HP:0000232
5 glomerulopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0100820
6 palpebral edema 59 32 hallmark (90%) Very frequent (99-80%) HP:0100540
7 abnormality of the immune system 59 32 hallmark (90%) Very frequent (99-80%) HP:0002715
8 aplasia/hypoplasia of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0008065
9 redundant skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0001582
10 generalized hyperpigmentation 59 32 hallmark (90%) Very frequent (99-80%) HP:0007440
11 renal insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0000083
12 abnormality of the cardiovascular system 59 32 frequent (33%) Frequent (79-30%) HP:0001626
13 morphological abnormality of the gastrointestinal tract 59 32 frequent (33%) Frequent (79-30%) HP:0012718
14 nephrotic syndrome 59 32 frequent (33%) Frequent (79-30%) HP:0000100
15 inguinal hernia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000023
16 abnormality of vision 59 32 occasional (7.5%) Occasional (29-5%) HP:0000504
17 hyperkeratosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000962
18 talipes equinovarus 59 32 occasional (7.5%) Occasional (29-5%) HP:0001762
19 impaired pain sensation 59 32 occasional (7.5%) Occasional (29-5%) HP:0007328
20 ureteral stenosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000071
21 hemiparesis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001269
22 alopecia of scalp 32 occasional (7.5%) HP:0002293
23 abnormality of the eye 59 Occasional (29-5%)
24 abnormality of nervous system morphology 59 Frequent (79-30%)
25 scalp hair loss 59 Occasional (29-5%)

GenomeRNAi Phenotypes related to Amyloidosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 APOA1 APOE APP B2M CST3 FGA

MGI Mouse Phenotypes related to Amyloidosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 APOA1 APOE APP B2M CST3 FGA
2 hematopoietic system MP:0005397 10.25 APOE APP B2M FGA GPNMB GSN
3 cardiovascular system MP:0005385 10.18 APOA1 APOE APP B2M CST3 FGA
4 immune system MP:0005387 10.18 APOE APP B2M FGA GPNMB GSN
5 integument MP:0010771 10.06 APOA1 APOE APP B2M FGA GSN
6 digestive/alimentary MP:0005381 10 APOE B2M FGA LYZ NLRP3 TNFRSF1A
7 liver/biliary system MP:0005370 9.91 APOA1 APOE B2M FGA LYZ MEFV
8 nervous system MP:0003631 9.85 APOE APP B2M CST3 FGA GPNMB
9 reproductive system MP:0005389 9.65 APOE APP B2M CST3 FGA GSN
10 skeleton MP:0005390 9.28 APOE FGA GSN IAPP IL31RA LYZ

Drugs & Therapeutics for Amyloidosis

Drugs for Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Colchicine Approved Phase 4 64-86-8 6167 2833
2
Citalopram Approved Phase 4 59729-33-8 2771
3 Tubulin Modulators Phase 4
4 Antimitotic Agents Phase 4
5 Fluorides Phase 4
6 Antiparkinson Agents Phase 4
7 Autonomic Agents Phase 4
8 Neurotransmitter Agents Phase 4
9 Neurotransmitter Uptake Inhibitors Phase 4
10 Serotonin Uptake Inhibitors Phase 4
11 Parasympatholytics Phase 4
12 Antidepressive Agents Phase 4
13 Antidepressive Agents, Second-Generation Phase 4
14 Cholinergic Agents Phase 4
15 Muscarinic Antagonists Phase 4
16 Serotonin Agents Phase 4
17 Cholinergic Antagonists Phase 4
18 Psychotropic Drugs Phase 4
19 Omega 3 Fatty Acid Phase 4
20
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
21
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
22
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
23
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
24
Morphine Approved, Investigational Phase 3 57-27-2 5288826
25
Ondansetron Approved Phase 3 99614-02-5 4595
26
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
27
Dalteparin Approved Phase 3 9005-49-6
28
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
29
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
32
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
33
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
34 Daratumumab Approved Phase 3 945721-28-8
35
Lenalidomide Approved Phase 3 191732-72-6 216326
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
38
Ixazomib Approved, Investigational Phase 3 1072833-77-2
39
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
40
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
41
Melphalan Approved Phase 3 148-82-3 460612 4053
42
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
43
Lenograstim Approved, Investigational Phase 3 135968-09-1
44
Creatine Approved, Investigational, Nutraceutical Phase 3 57-00-1 586
45
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
46
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
47
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
48 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
49
Taurochenodeoxycholic acid Experimental Phase 3 516-35-8 387316
50
Tauroursodeoxycholic acid Experimental, Investigational Phase 3 14605-22-2 12443252

Interventional clinical trials:

(show top 50) (show all 374)
# Name Status NCT ID Phase Drugs
1 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial Completed NCT02602028 Phase 4 colchicine
2 Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Recruiting NCT01683825 Phase 4 F-18 florbetapir PET
3 The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis Recruiting NCT03040427 Phase 4 F-18 florbetapir
4 Escitalopram Effects on CSF Amyloid Beta Total Concentrations Active, not recruiting NCT02161458 Phase 4 Escitalopram 20mg for 2 weeks;Escitalopram 20mg for 8 weeks;Escitalopram 30mg for 8 weeks;Placebo
5 A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy Not yet recruiting NCT03333551 Phase 4 F18 Florbetapir (amyvid) cardiac PET/CT imaging
6 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
7 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis Completed NCT01215747 Phase 3 KIACTA (eprodisate disodium);Placebo
9 Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial . Completed NCT00344526 Phase 3 Melphalan;Dexamethasone
10 APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) Completed NCT01960348 Phase 3 patisiran (ALN-TTR02);Sterile Normal Saline (0.9% NaCl)
11 A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
12 Induction Therapy With Bortezomib and Dexamethasone Followed by Autologous Stem Cell Transplantation Versus Autologous Stem Cell Transplantation Alone in the Treatment of AL Amyloidosis Completed NCT01998503 Phase 3 Bortezomib;dexamethasone;Melphalan
13 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
14 A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Completed NCT02319005 Phase 3 Revusiran (ALN-TTRSC);Sterile Normal Saline (0.9% NaCl)
15 The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study Completed NCT01435655 Phase 3 tafamidis
16 Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL) Completed NCT00477971 Phase 3 dexamethasone;melphalan
17 A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation Completed NCT01078454 Phase 3 melphalan;dexamethasone;bortezomib
18 A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem Completed NCT01165554 Phase 3 [18F] Flutemetamol
19 A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40 Completed NCT01265394 Phase 3 [18F] Flutemetamol
20 A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM) Completed NCT01994889 Phase 3 Tafamidis;Tafamidis;Placebo
21 A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study) Completed NCT01737398 Phase 2, Phase 3 Inotersen;Placebo
22 A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis Completed NCT01277016 Phase 3 BMDex
23 An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF)) Completed NCT02911857 Phase 3
24 Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
25 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
26 A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Completed NCT01705756 Phase 3 Kineret
27 Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
28 A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs Completed NCT02059291 Phase 3 Canakinumab;Placebo
29 A Phase III Study of the Correlation Between Florbetapir F 18 (18F-AV-45) PET Imaging and Amyloid Pathology Completed NCT00857415 Phase 3 florbetapir F 18
30 An Open-Label Extension Of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3 Fx-1006A
31 Application of Amyloid PET in Cerebral Amyloid Angiopathy Completed NCT03542656 Phase 3 amyloid PET
32 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
33 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
34 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
35 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
36 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
37 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
38 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
39 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
40 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
41 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
42 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
43 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
44 An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant Recruiting NCT03862807 Phase 3 Patisiran
45 HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) Recruiting NCT03759379 Phase 3 Patisiran;Vutrisiran (ALN-TTRSC02)
46 A Phase III Randomized Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin Recruiting NCT03481972 Phase 3 Doxycycline and tauroursodeoxycholic acid;Standard of care
47 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis Recruiting NCT03201965 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone, 40 mg;Daratumumab
48 A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM) Recruiting NCT02791230 Phase 3 Tafamidis
49 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM) Recruiting NCT03860935 Phase 3 AG10;Placebo Oral Tablet
50 A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy Recruiting NCT03474458 Phase 2, Phase 3 Doxycycline;Standard of care therapy

Search NIH Clinical Center for Amyloidosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylcysteine
Colchicine
Melphalan

Cochrane evidence based reviews: amyloidosis

Genetic Tests for Amyloidosis

Anatomical Context for Amyloidosis

MalaCards organs/tissues related to Amyloidosis:

41
Heart, Kidney, Liver, Brain, Bone, Lung, Skin

Publications for Amyloidosis

Articles related to Amyloidosis:

(show top 50) (show all 21600)
# Title Authors PMID Year
1
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. 38 17
31268366 2019
2
Noninvasive diagnosis of hereditary transthyretin-related cardiac amyloidosis: A case report. 38 17
31348283 2019
3
Multiple myeloma with onset of pancreas involvement: A case report. 38 17
31348284 2019
4
Investigation of AGE, their receptor and NF-kappaB activation and apoptosis in patients with ATTR and Gelsolin amyloidosis. 9 38
20376775 2010
5
Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. 9 38
20434879 2010
6
Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. 9 38
20462362 2010
7
Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. 9 38
20211733 2010
8
In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET. 9 38
20016895 2010
9
Currents concepts on the immunopathology of amyloidosis. 9 38
19626465 2010
10
Lack of evidence for OSMR and RET gene mutations in a Chinese family with friction melanosis. 9 38
19594765 2010
11
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. 9 38
20052750 2010
12
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. 9 38
20133122 2010
13
Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. 9 38
19911184 2010
14
Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding. 9 38
19950966 2010
15
Modeling an anti-amyloid combination therapy for Alzheimer's disease. 9 38
20371462 2010
16
Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. 9 38
19922329 2009
17
The 8 and 5 kDa fragments of plasma gelsolin form amyloid fibrils by a nucleated polymerization mechanism, while the 68 kDa fragment is not amyloidogenic. 9 38
19904968 2009
18
Retraction. Withdrawn: Severe ataxia with neuropathy in hereditary gelsolin amyloidosis. 9 38
19842787 2009
19
Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. 9 38
19861125 2009
20
Hereditary gelsolin amyloidosis mimicking Sjögren's syndrome. 9 38
19701715 2009
21
Clusterin regulates transthyretin amyloidosis. 9 38
19664600 2009
22
Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. 9 38
19781421 2009
23
[Systemic amyloidoses in renal biopsy samples]. 9 38
19764159 2009
24
Current perspectives on familial Mediterranean fever. 9 38
19339884 2009
25
Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. 9 38
19445625 2009
26
Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. 9 38
19324996 2009
27
Outcome of renal transplant in hereditary gelsolin amyloidosis. 9 38
19440061 2009
28
[Cardiac amyloidosis--cardiovascular magnetic resonance imaging as a valuable diagnostic tool]. 9 38
19340749 2009
29
Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. 9 38
19468344 2009
30
Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis. 9 38
19199031 2009
31
Laryngeal presentation of systemic apolipoprotein A-I-derived amyloidosis. 9 38
19235761 2009
32
Biochemical characterisation of amyloid by endomyocardial biopsy. 9 38
19291509 2009
33
Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells. 9 38
19065606 2009
34
A new role for the neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) in podocyte process formation and podocyte injury in human glomerulopathies. 9 38
18985619 2009
35
Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. 9 38
19033248 2009
36
Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. 9 38
19041304 2009
37
Immunotargeting of apolipoprotein E in amyloid: an initial trial in mice. 9 38
19429798 2009
38
[Familial transthyretin amyloidosis]. 9 38
20143571 2009
39
A molecular correlate of clinicopathology in transthyretin amyloidosis. 9 38
19061244 2009
40
Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress. 9 38
19137068 2009
41
Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. 9 38
19125186 2009
42
Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. 9 38
18984591 2009
43
Prevention of amyloidosis in familial Mediterranean fever with colchicine: a case-control study in Armenia. 9 38
19797919 2009
44
Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. 9 38
19808299 2008
45
Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. 9 38
19036982 2008
46
MEFV mutations in Japanese rheumatoid arthritis patients. 9 38
19210876 2008
47
Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models. 9 38
18357510 2008
48
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. 9 38
18537267 2008
49
Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. 9 38
18379834 2008
50
Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. 9 38
18463098 2008

Variations for Amyloidosis

ClinVar genetic disease variations for Amyloidosis:

6 (show top 50) (show all 51)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 GSN NM_001127666.2(GSN): c.814G> A (p.Val272Ile) single nucleotide variant Uncertain significance rs745588757 9:124079391-124079391 9:121317113-121317113
2 GSN NM_001127666.2(GSN): c.1586G> A (p.Arg529His) single nucleotide variant Uncertain significance rs769400986 9:124088926-124088926 9:121326648-121326648
3 GSN NM_001127666.2(GSN): c.1610G> A (p.Arg537Gln) single nucleotide variant Uncertain significance rs528604896 9:124088950-124088950 9:121326672-121326672
4 GSN NM_001127666.2(GSN): c.*205G> A single nucleotide variant Uncertain significance rs779431879 9:124095086-124095086 9:121332808-121332808
5 GSN NM_000177.4(GSN): c.-36C> T single nucleotide variant Uncertain significance rs886063404 9:124062104-124062104 9:121299826-121299826
6 GSN NM_001127666.2(GSN): c.1070G> A (p.Arg357Gln) single nucleotide variant Uncertain significance rs372681751 9:124081004-124081004 9:121318726-121318726
7 GSN NM_001127666.2(GSN): c.579T> G (p.Asn193Lys) single nucleotide variant Uncertain significance rs752698745 9:124074649-124074649 9:121312371-121312371
8 GSN NM_001127666.2(GSN): c.1224+4C> T single nucleotide variant Uncertain significance rs372713895 9:124081162-124081162 9:121318884-121318884
9 GSN NM_001127666.2(GSN): c.1588G> A (p.Ala530Thr) single nucleotide variant Uncertain significance rs147554026 9:124088928-124088928 9:121326650-121326650
10 GSN NM_001127666.2(GSN): c.*116_*117insGTG insertion Uncertain significance rs751044080 9:124094997-124094998 9:121332719-121332720
11 GSN NM_001127666.2(GSN): c.*185G> A single nucleotide variant Uncertain significance rs757682798 9:124095066-124095066 9:121332788-121332788
12 GSN NM_001127666.2(GSN): c.-47-114G> A single nucleotide variant Uncertain significance rs886063405 9:124062220-124062220 9:121299942-121299942
13 GSN NM_001127666.2(GSN): c.156C> T (p.Gly52=) single nucleotide variant Uncertain significance rs774617795 9:124064372-124064372 9:121302094-121302094
14 GSN NM_001127666.2(GSN): c.756G> A (p.Ala252=) single nucleotide variant Uncertain significance rs377624593 9:124076271-124076271 9:121313993-121313993
15 GSN NM_001127666.2(GSN): c.*97_*98GT[11] short repeat Uncertain significance rs147410423 9:124094996-124094997 9:121332718-121332719
16 GSN NM_001127666.2(GSN): c.*116_*117insG insertion Uncertain significance rs751044080 9:124094997-124094998 9:121332719-121332720
17 GSN NM_001127666.2(GSN): c.*120_*121insG insertion Uncertain significance rs886063409 9:124095001-124095002 9:121332723-121332724
18 GSN NM_001127666.2(GSN): c.*124_*125insC insertion Uncertain significance rs886063410 9:124095005-124095006 9:121332727-121332728
19 GSN NM_001127666.2(GSN): c.*126T> C single nucleotide variant Uncertain significance rs886063411 9:124095007-124095007 9:121332729-121332729
20 GSN NM_001127666.2(GSN): c.*194G> A single nucleotide variant Uncertain significance rs886063412 9:124095075-124095075 9:121332797-121332797
21 GSN NM_001127666.2(GSN): c.*136dup duplication Uncertain significance rs71680051 9:124095017-124095017 9:121332739-121332739
22 GSN NM_001127666.2(GSN): c.*97_*98GT[13] short repeat Uncertain significance rs147410423 9:124094992-124094997 9:121332714-121332719
23 GSN NM_001127666.2(GSN): c.1975A> G (p.Met659Val) single nucleotide variant Uncertain significance rs886063406 9:124091570-124091570 9:121329292-121329292
24 GSN NM_001127666.2(GSN): c.2035G> A (p.Glu679Lys) single nucleotide variant Uncertain significance rs886063407 9:124093702-124093702 9:121331424-121331424
25 GSN NM_001127666.2(GSN): c.*97_*98insGGTG insertion Uncertain significance rs886063408 9:124094978-124094979 9:121332700-121332701
26 DSP NM_004415.4(DSP): c.6577G> A (p.Glu2193Lys) single nucleotide variant Uncertain significance rs397516952 6:7584072-7584072 6:7583839-7583839
27 GSN NM_001127666.2(GSN): c.2079G> A (p.Thr693=) single nucleotide variant Likely benign rs747385746 9:124094731-124094731 9:121332453-121332453
28 GSN NM_001127666.2(GSN): c.1815G> A (p.Leu605=) single nucleotide variant Likely benign rs139239940 9:124091188-124091188 9:121328910-121328910
29 GSN NM_001127666.2(GSN): c.1964C> T (p.Thr655Met) single nucleotide variant Likely benign rs144434647 9:124091559-124091559 9:121329281-121329281
30 GSN NM_001127666.2(GSN): c.1568C> G (p.Thr523Ser) single nucleotide variant Likely benign rs77681311 9:124088908-124088908 9:121326630-121326630
31 GSN NM_001127666.2(GSN): c.1131G> A (p.Val377=) single nucleotide variant Likely benign rs201325199 9:124081065-124081065 9:121318787-121318787
32 GSN NM_001127666.2(GSN): c.1321C> T (p.Arg441Cys) single nucleotide variant Likely benign rs116185403 9:124083642-124083642 9:121321364-121321364
33 GSN NM_001127666.2(GSN): c.304C> T (p.Arg102Trp) single nucleotide variant Likely benign rs146956976 9:124065263-124065263 9:121302985-121302985
34 GSN NM_001127666.2(GSN): c.415G> A (p.Val139Met) single nucleotide variant Likely benign rs41305623 9:124072992-124072992 9:121310714-121310714
35 GSN NM_001127666.2(GSN): c.1272A> G (p.Thr424=) single nucleotide variant Likely benign rs149375418 9:124083593-124083593 9:121321315-121321315
36 GSN NM_001127666.2(GSN): c.1454G> A (p.Arg485His) single nucleotide variant Likely benign rs142828669 9:124088794-124088794 9:121326516-121326516
37 GSN NM_001127666.2(GSN): c.196G> A (p.Gly66Arg) single nucleotide variant Likely benign rs556563870 9:124064412-124064412 9:121302134-121302134
38 GSN NM_001127666.2(GSN): c.1696G> A (p.Val566Met) single nucleotide variant Likely benign rs151208452 9:124089661-124089661 9:121327383-121327383
39 GSN NM_001127666.2(GSN): c.1596C> T (p.Ser532=) single nucleotide variant Likely benign rs140414249 9:124088936-124088936 9:121326658-121326658
40 GSN NM_001127666.2(GSN): c.229+7C> T single nucleotide variant Likely benign rs146379508 9:124064452-124064452 9:121302174-121302174
41 GSN NM_001127666.2(GSN): c.276C> T (p.Thr92=) single nucleotide variant Likely benign rs116956127 9:124065235-124065235 9:121302957-121302957
42 GSN NM_001127666.2(GSN): c.1203C> T (p.Asp401=) single nucleotide variant Likely benign rs147583697 9:124081137-124081137 9:121318859-121318859
43 GSN NM_001127666.2(GSN): c.1258G> A (p.Val420Met) single nucleotide variant Likely benign rs140042418 9:124083579-124083579 9:121321301-121321301
44 GSN NM_001127666.2(GSN): c.1520A> G (p.Tyr507Cys) single nucleotide variant Likely benign rs139832048 9:124088860-124088860 9:121326582-121326582
45 GSN NM_001127666.2(GSN): c.1546G> A (p.Gly516Arg) single nucleotide variant Likely benign rs58750568 9:124088886-124088886 9:121326608-121326608
46 GSN NM_001127666.2(GSN): c.62A> G (p.Lys21Arg) single nucleotide variant Benign rs115224458 9:124064278-124064278 9:121302000-121302000
47 GSN NM_001127666.2(GSN): c.265G> A (p.Ala89Thr) single nucleotide variant Benign rs2230287 9:124065224-124065224 9:121302946-121302946
48 GSN NM_001127666.2(GSN): c.1293C> T (p.Gly431=) single nucleotide variant Benign rs2304393 9:124083614-124083614 9:121321336-121321336
49 GSN NM_001127666.2(GSN): c.1727C> T (p.Thr576Met) single nucleotide variant Benign rs76463933 9:124089692-124089692 9:121327414-121327414
50 GSN NM_001127666.2(GSN): c.2148T> C (p.Phe716=) single nucleotide variant Benign rs9102 9:124094800-124094800 9:121332522-121332522

Expression for Amyloidosis

Search GEO for disease gene expression data for Amyloidosis.

Pathways for Amyloidosis

Pathways related to Amyloidosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 TTR TNFRSF1A SERPINA3 SAA1 OSMR NLRP3
2
Show member pathways
13.37 TTR SAA1 LYZ IAPP GSN FGA
3
Show member pathways
13.32 TTR SAA1 NLRP3 LYZ IAPP GSN
4 11.74 GSN APOE APOA1
5
Show member pathways
11.64 NLRP3 MEFV APP
6
Show member pathways
11.56 SAA1 APOE APOA1
7
Show member pathways
11.43 SERPINA3 SAA4 SAA2 SAA1 APOE APOA1
8 10.71 SERPINA3 OSMR
9 10.44 SAA1 APP

GO Terms for Amyloidosis

Cellular components related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.97 TNFRSF1A FGA B2M APP APOA1
2 collagen-containing extracellular matrix GO:0062023 9.86 SERPINA3 FGA APOE APOA1
3 extracellular region GO:0005576 9.83 TTR TNFRSF1A SERPINA3 SAA4 SAA1 NLRP3
4 receptor complex GO:0043235 9.81 TNFRSF1A OSMR IL31RA APP
5 endoplasmic reticulum lumen GO:0005788 9.8 FGA CST3 B2M APP APOE APOA1
6 blood microparticle GO:0072562 9.77 SERPINA3 GSN FGA APOE APOA1
7 secretory granule lumen GO:0034774 9.76 SERPINA3 GSN APOA1
8 azurophil granule lumen GO:0035578 9.71 TTR SERPINA3 LYZ
9 platelet alpha granule lumen GO:0031093 9.7 SERPINA3 FGA APP
10 tertiary granule lumen GO:1904724 9.67 LYZ CST3 B2M
11 extracellular vesicle GO:1903561 9.65 FGA APOE APOA1
12 very-low-density lipoprotein particle GO:0034361 9.59 APOE APOA1
13 endocytic vesicle lumen GO:0071682 9.58 SAA1 APOE APOA1
14 low-density lipoprotein particle GO:0034362 9.57 APOE APOA1
15 chylomicron GO:0042627 9.55 APOE APOA1
16 high-density lipoprotein particle GO:0034364 9.55 SAA4 SAA2 SAA1 APOE APOA1
17 extracellular space GO:0005615 9.5 TTR TNFRSF1A SERPINA3 SAA4 SAA2 SAA1
18 intermediate-density lipoprotein particle GO:0034363 9.46 APOE APOA1
19 discoidal high-density lipoprotein particle GO:0034365 9.43 APOE APOA1
20 extracellular exosome GO:0070062 10.07 TTR SERPINA3 SAA4 SAA2 SAA1 LYZ

Biological processes related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.94 TNFRSF1A SAA1 OSMR IL31RA
2 inflammatory response GO:0006954 9.91 TNFRSF1A SERPINA3 NLRP3 MEFV LYZ
3 post-translational protein modification GO:0043687 9.89 FGA CST3 APP APOE APOA1
4 innate immune response GO:0045087 9.85 SAA1 NLRP3 MEFV FGA B2M APP
5 negative regulation of peptidase activity GO:0010466 9.84 SERPINA3 CST3 APP
6 cholesterol metabolic process GO:0008203 9.8 APP APOE APOA1
7 cell chemotaxis GO:0060326 9.8 SAA4 SAA2 SAA1
8 neutrophil degranulation GO:0043312 9.8 TTR SERPINA3 LYZ GSN CST3 B2M
9 defense response GO:0006952 9.73 TNFRSF1A NLRP3 IL31RA CST3
10 retinoid metabolic process GO:0001523 9.71 TTR APOE APOA1
11 platelet degranulation GO:0002576 9.71 SERPINA3 FGA APP APOA1
12 reverse cholesterol transport GO:0043691 9.66 APOE APOA1
13 positive regulation of lipid biosynthetic process GO:0046889 9.65 APOE APOA1
14 high-density lipoprotein particle remodeling GO:0034375 9.65 APOE APOA1
15 negative regulation of interleukin-1 beta secretion GO:0050713 9.64 NLRP3 APOA1
16 high-density lipoprotein particle assembly GO:0034380 9.63 APOE APOA1
17 phospholipid efflux GO:0033700 9.62 APOE APOA1
18 negative regulation of long-term synaptic potentiation GO:1900272 9.61 APP APOE
19 high-density lipoprotein particle clearance GO:0034384 9.61 APOE APOA1
20 chylomicron assembly GO:0034378 9.6 APOE APOA1
21 very-low-density lipoprotein particle remodeling GO:0034372 9.59 APOE APOA1
22 positive regulation of cholesterol esterification GO:0010873 9.58 APOE APOA1
23 amyloid fibril formation GO:1990000 9.58 GSN APP
24 chylomicron remodeling GO:0034371 9.57 APOE APOA1
25 regulation of cholesterol transport GO:0032374 9.56 APOE APOA1
26 positive chemotaxis GO:0050918 9.56 SAA4 SAA2 SAA1 GPNMB
27 regulation of Cdc42 protein signal transduction GO:0032489 9.55 APOE APOA1
28 lipoprotein biosynthetic process GO:0042158 9.52 APOE APOA1
29 regulation of tissue remodeling GO:0034103 9.48 GPNMB CST3
30 positive regulation of amyloid fibril formation GO:1905908 9.46 APP APOE
31 acute-phase response GO:0006953 9.46 SERPINA3 SAA4 SAA2 SAA1
32 negative regulation of inflammatory response GO:0050728 9.43 TNFRSF1A SAA1 NLRP3 MEFV APOE APOA1
33 cellular protein metabolic process GO:0044267 9.36 TTR SAA1 LYZ IAPP GSN FGA
34 immune system process GO:0002376 10.04 NLRP3 MEFV IL31RA FGA B2M

Molecular functions related to Amyloidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase inhibitor activity GO:0030414 9.61 SERPINA3 CST3 APP
2 heparin binding GO:0008201 9.56 SAA1 GPNMB APP APOE
3 amyloid-beta binding GO:0001540 9.46 IAPP CST3 APOE APOA1
4 cholesterol transporter activity GO:0017127 9.4 APOE APOA1
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.37 APOE APOA1
6 lipoprotein particle binding GO:0071813 9.32 APOE APOA1
7 identical protein binding GO:0042802 9.32 TTR NLRP3 MEFV LYZ IAPP CST3
8 chemoattractant activity GO:0042056 9.26 SAA4 SAA2 SAA1 GPNMB

Sources for Amyloidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....